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Research Letter
Synchronized
Diaphragmatic Stimulation
for the Treatment of
Symptomatic Heart Failure

SDS can improve cardiac ﬁlling, cardiovascular pressure conditions, and systolic cardiac performance. 2
SDS modulates the intrathoracic pressure through a
localized contraction of the diaphragm facilitated by
stimulating the diaphragmatic muscle in concert with
the cardiac cycle. Because the stimulation is not targeting the phrenic nerve but rather the slow

A Novel Implantable Therapy Concept

responding type-I diaphragmic muscle ﬁbers, the
corresponding diaphragmatic “twitch” is clinically

Despite successes in pharmacologic and device ther-

impactful yet does not affect respiration and is also

apy for patients with heart failure with reduced

not perceptible to the patient.2,3

ejection fraction (HFrEF), the majority of patients

The SDS concept has been validated through a se-

remain symptomatic, quality of life is often impaired,

ries of preclinical studies and human pilot studies. In

and episodes of decompensation are common with a

humans, SDS has been investigated in the acute

shortened life expectancy. For patients with HFrEF in

setting3 of post coronary artery bypass graft surgery

sinus rhythm and prolonged QRS duration, cardiac

and in the chronic setting of CRT, where Beeler et al2

resynchronization therapy (CRT) is often highly

reported on a small, randomized crossover trial that

effective. There is an unmet need for patients with

used a CRT device to deliver diaphragmatic stimula-

HFrEF who are not candidates for CRT but remain

tion synchronized to atrioventricular delay optimized

symptomatic despite maximally tolerated guideline-

and simultaneous biventricular pacing. Three weeks

directed medical therapy, which inspired the US

of diaphragmatic pacing improved breathlessness,

Food and Drug Administration to grant Breakthrough

exercise capacity, and left ventricular ejection frac-

Device Designations for promising technologies to

tion (LVEF) over CRT therapy alone. Improvements in

close that treatment gap. 1 Synchronized diaphrag-

LVEF were sustained for up to 1 year.4 In this study,

matic stimulation (SDS) is recognized by the U.S.

the stimulation lead was placed on the superior side

Food and Drug Administration as a breakthrough

of the diaphragm at the end of the coronary artery

device. SDS is a novel approach designed to improve

bypass graft procedure, and the lead was connected

cardiac function, symptoms, and, ultimately, out-

to the pulse generator when the CRT implant

comes for patients who are symptomatic for HFrEF.

occurred weeks later. While this approach is attrac-

Elevated intracardiac pressures are the hallmark of

tive for patients indicated for coronary artery bypass

heart failure (HF) and a key pathological driver of

graft procedure as well as pacing therapy, it would

disease progression and limited exertional capacity.

only address a segment of patients who are symp-

The degree of cardiac pressure elevation is deter-

tomatic for HF that are no longer responding to

mined by preload, afterload, and pericardial restraint.

guideline-directed medical therapy.

The pericardium restrains the heart, and the degree of

An implantable SDS therapy system has been

restraint is determined by the pericardial structure

developed that overcomes those restrictions with a

itself and the intrathoracic pressure. This aspect of

minimally invasive implantation technique and a

HF pathophysiology is among the fundamental

low-risk proﬁle that allows outpatient implantation.

drivers behind the SDS therapy concept. SDS induces

The system consists of an implantable pulse gener-

a temporal modulation of intrathoracic pressure with

ator, stimulating/sensing leads suitable for an inferior

a resultant reduction in pericardial restraint, leading

diaphragmatic placement, and a tailored surgical de-

to improved cardiac ﬁlling and reduced afterload.

livery tool to facilitate implantation through a lapa-

When applied at the right time in the cardiac cycle,

roscopic procedure.
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F I G U R E 1 SDS Mechanism of Action and Study Results

Synchronized diaphragmatic stimulation (SDS) is delivered through a novel extracardiac device by stimulating the diaphragm in concert with
the cardiac cycle. SDS improved exercise tolerance, quality of life (QOL), and echocardiographic functional measures over 12 months.
LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic function.

The ﬁrst-in-human, single-arm, open-label study

treatment of patients with HFrEF, who remain symp-

with the SDS therapy system enrolled 15 men who

tomatic despite maximal guideline-directed medical

were symptomatic for HFrEF, New York Heart Asso-

therapy. Encouraging study results to date now need

ciation functional class II/III, and ischemic heart dis-

to be validated in a randomized clinical trial.

ease.5 Implant success was 100%. Patients were

SF-36 QOL survey), 6-minute hall walk distance, and
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by echocardiography. No implantation procedure or
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evaluated at 3, 6, and 12 months for device- or leadrelated complications, quality of life (determined by

adverse

event

occurred

throughout

12-month follow-up, and patients did not sense
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the ongoing diaphragmatic stimulation. Signiﬁcant
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median values decreased for the following: left ven-
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tricular end-systolic volume 136 (IQR: 123-170) to 98
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(IQR: 89-106) mL (P ¼ 0.05); 6-minute hall walk distance (at discharge 315 [IQR: 300-330] vs at 12 months
340 [IQR: 315-368] m; P ¼ 0.004), and SF-36 QOL for
physical scale (at discharge 0 [IQR: 0-0] vs at 6 months
38 [IQR: 0-50] arbitrary units [AU]; P ¼ 0.002; at
12 months 25 [IQR: 0-50] AU; P ¼ 0.006). And median

The authors attest they are in compliance with human studies committees and
animal welfare regulations of the authors’ institutions and Food and Drug
Administration guidelines, including patient consent where appropriate. For
more information, visit the Author Center.
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